In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct

Overexpression of human epidermal growth factor receptor 3 (HER3) is involved in resistance to several therapies for malignant tumours. Currently, several anti-HER3 monoclonal antibodies are under clinical development. We introduce an alternative approach to HER3-targeted therapy based on engineered...

Descripción completa

Detalles Bibliográficos
Autores principales: Bass, Tarek Z., Rosestedt, Maria, Mitran, Bogdan, Frejd, Fredrik Y., Löfblom, John, Tolmachev, Vladimir, Ståhl, Stefan, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322329/
https://www.ncbi.nlm.nih.gov/pubmed/28230065
http://dx.doi.org/10.1038/srep43118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322329/
https://www.ncbi.nlm.nih.gov/pubmed/28230065
http://dx.doi.org/10.1038/srep43118

Ejemplares similares